Wegovy® (semaglutide) injection 2.4 mg
For chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m2 (obesity), or ≥27 kg/m2 (overweight) in the presence of a weight-related comorbidity, and for pediatric patients aged 12 years and older with an initial BMI at ≥95th percentile standardized for age and sex (obesity). Click for Limitations of Use.
Saxenda® (liraglutide) injection 3 mg
For chronic weight management as an adjunct to a reduced calorie diet and increased physical activity in adults with a BMI ≥30 kg/m2, or ≥27 kg/m2 with one or more weight-related comorbidities, and for patients aged 12-17 years with body weight above 60 kg (132 lbs) and an initial BMI corresponding to ≥30 kg/m2 for adults by international cut-offs. Click for Limitations of Use.